This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nymox To Present At Singular Research Annual "Best Of The Uncovereds" Research Conference

HASBROUCK HEIGHTS, N.J., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the Company will be presenting at the Singular Research Annual "Best of the Uncovereds" Conference in Los Angeles November 4, 2010.

Paul Averback, Nymox's CEO will present at the conference. During the remainder of the day, Dr. Averback will meet with investors during a series of one-on-one breakout meetings at the conference.

The conference is being held November 4, 2010 at the Luxe Sunset Boulevard Hotel in Los Angeles.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new NX-1207 drug for benign prostatic hyperplasia (BPH) is in Phase 3 development in the U.S., and has potential use in other clinical indications. The Company has other drugs in development, and offers NicAlert TM and TobacAlert TM tests for measuring tobacco product exposure, and AlzheimAlert TM, a test to aid in the diagnosis of Alzheimer's disease.

About Singular Research

Singular Research aims to be the most trusted supplier of independent research on small-cap companies. * Our analysts research companies generally that are not covered by any other firms. * We provide Honest Advice: Our Independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees. * Track Record: Our coverage list compounded annual performance since inception is 13.04% vs. 3.45% for the Russell 2000, from August 2004 through September 2010. Performance YTD in 2010 is 8.9% vs. 7.4% for the Russell 2000. http://www.singular-research.com/discover/broadcast-news.htm This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT:  Nymox Pharmaceutical Corporation
          Roy Wolvin
          1-800-936-9669
          info@nymox.com

          Singular Research
          Robert Maltbie, Jr., CFA
          818-222-6915
          robert@singularresearch.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs